Are Parmax Pharma Ltd latest results good or bad?

Parmax Pharma Ltd's latest financial results indicate significant operational distress. For the quarter ending December 2025, the company reported net sales of ₹2.53 crores, reflecting a year-on-year decline of 72.74% from ₹9.28 crores in the same quarter the previous year. This decline is indicative of severe challenges in maintaining customer contracts or market position. Although there was a sequential growth of 30.41% from the previous quarter, this improvement appears minimal and does not suggest a sustainable recovery. The company incurred a net loss of ₹0.73 crores, which represents an 87.20% deterioration compared to the previous quarter's loss. The operating margin plummeted to -62.85%, a stark contrast to the positive margin of 2.16% reported in the same quarter last year. This drastic margin compression highlights fundamental operational challenges rather than temporary setbacks. Parmax Pharma's balance sheet has also deteriorated, with negative shareholder funds of ₹-1.99 crores as of March 2025. The negative book value per share of ₹-4.47 raises concerns about the company's solvency and financial stability. The reliance on supplier credit is evident, as trade payables surged to ₹10.22 crores, indicating potential working capital stress. Overall, the financial data suggests that Parmax Pharma is facing a critical operational crisis, characterized by sustained losses, collapsing revenues, and significant balance sheet deterioration. The company saw an adjustment in its evaluation, reflecting the ongoing challenges it faces in the pharmaceutical sector.